Nivolumab Plus Low-Dose IPILIMUMAB as First-Line Treatment of Advanced NSCLC: Overall Survival Analysis of Checkmate 817
Fabrice Barlési,
Clarisse Audigier-Valette,
Enriqueta Felip,
T-E. Ciuleanu,
Kevin Jao,
Erika Rijavec,
László Urbán,
Jean-Sebastien Aucoin,
Cristina Zannori,
Karim Vermaelen,
Annals of Oncology · 2019 · 17 citations · 0 references